Transgene Biotek, a company in the Healthcare Service Provider industry, reported revenue of ₹0.06 crore and a net loss of ₹0.35 crore for the September 2026 quarter.
Transgene Biotek (BSE: TRABI) closed at ₹2.44 on 20 Nov 2026, down 32.2% over the past year. Its market capitalisation is ₹18 crore.
Incorporated in 1990, Transgene Biotek Ltd is in the business of Research & Development
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.